Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.

Abstract

The phase 2 study of idelalisib monotherapy for indolent non-Hodgkin lymphomas (iNHLs) was completed in 2018; final efficacy and safety data with up to 6.7 years long-term follow-up are reported. Patients with iNHL refractory to both rituximab and an alkylating agent were enrolled and received 150 mg idelalisib twice daily (N = 125). Idelalisib resulted in an overall response rate of 57.6% with 34.4% continuing therapy for ≥12 months. The median progression-free survival and duration of response were 11.0 and 11.8 months for follicular lymphoma, 22.2 and 20.4 months for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM), and 6.6 and 18.4 months for marginal zone lymphoma (MZL). Median overall survival after extended follow-up was 48.6 (95% CI 33.9, 71.7) months. Long-term follow-up did not reveal new safety concerns. These data indicate beneficial outcomes with longer follow-up after idelalisib for treatment of iNHL including in patients with LPL/WM and MZL.

• Authors: Nina D Wagner-Johnston, Stephen J Schuster, Sven deVos, Gilles Salles, Wojciech J Jurczak, Christopher R Flowers, Andreas Viardot, Ian W Flinn, Peter Martin, Guan Xing, Nishanthan Rajakumaraswamy, Ajay K Gopal
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 5 Pg. 1077-1087 (05 2021) ISSN: 1029-2403 [Electronic] United States
• PMID: 33300385 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Purines
• Quinazolinones
• Rituximab
• idelalisib

Topics

• Antineoplastic Combined Chemotherapy Protocols
• Follow-Up Studies
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Purines (adverse effects)
• Quinazolinones (adverse effects)
• Rituximab (adverse effects)